No abstract

Except for chemotherapy, surgery, and radiotherapy, photodynamic therapy (PDT) as new therapy modality is already in wide clinic use for the treatment of various diseases. The major bottleneck of this technique is the requirement of outer light source, which always limits effective application of PDT to the lesions in deeper tissue. Here, we first report a new modality for treating cancer and microbial infections, which is activated by chemical molecules instead of outer light irradiation. In this system, in situ bioluminescence of luminol can be absorbed by a cationic oligo(p-phenylene vinylene) (OPV) that acts as the photosensitizer through bioluminescence resonance energy transfer (BRET) process. The excited OPV sensitizes oxygen molecule in the surroundings to produce reactive oxygen species (ROS) that kill the adjacent cancer cells in vitro and in vivo, and pathogenic microbes. By avoiding the use of light irradiation, this work opens a new therapy modality to tumor and pathogen infections.

No abstract

We prepared a new conjugated polymer nanoparticle with the size of about 50 nm that is prepared by electrostatic assembly of cationic conjugated polymer PFO and anionic poly(l-glutamic acid) conjugated with anticancer drug doxorubicin (PFO/PG-Dox). The PFO exhibits good fluorescence quantum yield, photostability, and little cytotoxicity to meet the essential requests for cell imaging. In PFO/PG-Dox nanoparticles, the fluorescence of PFO is highly quenched by Dox by electron transfer mechanism, and thus the PFO is in the fluorescence "turn-off' state. After PFO/PG-Dox nanoparticles are exposed to carboxypeptidase or are taken up by cancer cells, the poly(l-glutamic acid) is hydrolysed to release the Dox, inducing the activation of PFO fluorescence to "turn-on" state. This multifunctional nanoparticle system can deliver Dox to targeted cancer cells and monitor the Dox release based on fluorescence "turn-on" signal of PFO, which concurrently images the cancer cells. The present work opens the door for new functional studies of conjugated polymer in simultaneous imaging and disease therapeutics.

Multifunctional materials that simultaneously provide therapeutic action and image the results provide new strategies for the treatment of various diseases. Here, it is shown that water soluble conjugated polymers with a molecular design centered on the polythiophene−porphyrin dyad are effective for killing neighboring cells. Following photoexcitation, energy is efficiently transferred from the polythiophene backbone to the porphyrin units, which readily produce singlet oxygen (1O2) that is toxic for the cells. Due to the light‐harvesting ability of the electronically delocalized backbone and the efficient energy transfer amongst optical partners, the polythiophene−porphyrin dyad shows a higher 1O2 generation efficiency than a small molecule analog. The fluorescent properties of these polymers can also serve to distinguish amongst living and dead cells. Polymers can be designed with folic acid grafted onto the polymer side chain that can specifically kill folate receptor‐overexpressed cells, thereby providing an important demonstration of anticancer specificity through molecular design.

A new water-soluble conjugated polymer containing fluorene and boron-dipyrromethene repeat units in the backbones (PBF) that exhibits red emission was synthesized and characterized. Cationic PBF forms uniform nanoparticles with negatively charged disodium salt 3,3'-dithiodipropionic acid (SDPA) in aqueous solution through electrostatic interactions. The nanoparticles display absorption maximum at 550 nm and emission maximum at 590 nm. Upon photoexcitation with white light (400-800 nm) with 90 and 45 mW·cm(-2) for bacteria and cancer cells killing respectively, PBF nanoparticles can sensitize the oxygen molecule to readily produce reactive oxygen species (ROS) for rapidly killing neighboring bacteria and cancer cells. Furthermore, PBF nanoparticles concurrently provide optical imaging capability. PBF nanoparticles are therefore a promising multifunctional material for treating cancers and bacteria infections, while concurrently providing optical monitoring capabilities.

BackgroundThe Pacific white shrimp, Litopenaeus vannamei, is a worldwide cultured crustacean species with important commercial value. Over the last two decades, Taura syndrome virus (TSV) has seriously threatened the shrimp aquaculture industry in the Western Hemisphere. To better understand the interaction between shrimp immune and TSV, we performed a transcriptome analysis in the hepatopancreas of L. vannamei challenged with TSV, using the 454 pyrosequencing (Roche) technology.Methodology/Principal FindingsWe obtained 126919 and 102181 high-quality reads from TSV-infected and non-infected (control) L. vannamei cDNA libraries, respectively. The overall de novo assembly of cDNA sequence data generated 15004 unigenes, with an average length of 507 bp. Based on BLASTX search (E-value <10−5) against NR, Swissprot, GO, COG and KEGG databases, 10425 unigenes (69.50% of all unigenes) were annotated with gene descriptions, gene ontology terms, or metabolic pathways. In addition, we identified 770 microsatellites and designed 497 sets of primers. Comparative genomic analysis revealed that 1311 genes differentially expressed in the infected shrimp compared to the controls, including 559 up- and 752 down- regulated genes. Among the differentially expressed genes, several are involved in various animal immune functions, such as antiviral, antimicrobial, proteases, protease inhibitors, signal transduction, transcriptional control, cell death and cell adhesion.Conclusions/SignificanceThis study provides valuable information on shrimp gene activities against TSV infection. Results can contribute to the in-depth study of candidate genes in shrimp immunity, and improves our current understanding of this host-virus interaction. In addition, the large amount of transcripts reported in this study provide a rich source for identification of novel genes in shrimp.

The insulin-like growth factor binding protein 5 (IGFBP5), which is often dysregulated in human cancers, plays a crucial role in carcinogenesis and cancer development. However, the function and underlying mechanism of IGFBP5 in tumor growth and metastasis has been elusive, particularly in malignant human melanoma. Here, we reported that IGFBP5 acts as an important tumor suppressor in melanoma tumorigenicity and metastasis by a series of experiments including transwell assay, xenograft model, in vivo tumor metastasis experiment, and RNA-Seq. Overexpression of IGFBP5 in A375, a typical human melanoma cell line, inhibited cell malignant behaviors significantly, including in vitro proliferation, anchorage-independent growth, migration and invasion, as well as in vivo tumor growth and pulmonary metastasis. In addition, overexpression of IGFBP5 suppressed epithelial-mesenchymal transition (EMT), and decreased the expression of E-cadherin and the key stem cell markers NANOG, SOX2, OCT4, KLF4, and CD133. Furthermore, IGFBP5 exerts its inhibitory activities by reducing the phosphorylation of IGF1R, ERK1/2, and p38-MAPK kinases and abating the expression of HIF1α and its target genes, VEGF and MMP9. All these findings were confirmed by IGFBP5 knockdown in human melanoma cell line A2058. Taken together, these results shed light on the mechanism of IGFBP5 as a potential tumor-suppressor in melanoma progression, indicating that IGFBP5 might be a novel therapeutic target for human melanoma.